Latest Whitepapers

The SomaScan Assay is an ideal high throughput platform for identifying proteins that may be involved in disease pathology, as it offers a highly sensitive method of quantifying proteins in different biologic fluids such as serum, plasma, urine and cerebrospinal fluid.

Only a small amount of cell-free DNA (cfDNA) can be found in circulation, therefore efficient and highly sensitive technologies such as next-generation sequencing (NGS) are typically being used to detect this biomarker.

Many regulatory guidelines state that cell banks and cultures used in the production of biologics must be tested for mycoplasma. Mycoplasma infections can cause severe problems in manufacturing as these organisms can alter DNA, RNA and modify host cell plasma membrane antigens.

GeoMx® Human Whole Transcriptome Atlas

Traditional gene expression technologies are unable to capture heterogeneity of the transcriptome with spatial context.

Spatially resolved biology allows researchers to study cells in the context of their tissue microenvironment, enabling a fuller appreciation of cellular function.

The need for molecular diagnostic assays is growing at an unprecedented rate and the discovery of new biomarkers and improved accessibility to standard catalog reagents has allowed the creation of molecular tests faster than ever before.

Download this whitepaper to review the exciting technology behind the advances in data independent acquisition and explore how it can enhance your research.

Many novel cell and gene therapies have the potential to offer personalized therapeutic approaches and hold great promise for curing or treating diseases.

Nonalcoholic steatohepatitis (NASH) is an aggressive form of nonalcoholic fatty liver disease (NAFLD), a liver condition that is characterized by liver steatosis accompanied by liver cell injury and inflammation.

Download this whitepaper to uncover predicting disease onset via clinical biomarkers as well as other potential applications in diabetes research.